ResMed Inc. (RMD) News
Filter RMD News Items
RMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RMD News Highlights
- For RMD, its 30 day story count is now at 9.
- Over the past 20 days, the trend for RMD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ASX, DEC and BODY are the most mentioned tickers in articles about RMD.
Latest RMD News From Around the Web
Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The |
Resmed posts notice about risk of mask magnets interfering with medical implantsLike its rival Philips, Resmed has determined that patients should not wear magnetized masks near some implants. |
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical DevicesResMed’s masks with magnets are safe when used in accordance with the updated Instructions for UseSAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. This voluntary field correction does not require a return of a mask with magnets unless the patient is contr |
Resmed hails ‘significant victory’ as patent board rules in dispute with NYUThe decisions invalidate claims that NYU argued were infringed by Resmed’s sleep apnea devices. |
Here's Why Investors Should Retain ResMed (RMD) Stock for NowInvestors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business. |
ResMed Secures Significant Victory in Patent Fight Against New York UniversitySAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims New York University (NYU) asserted against ResMed, based on seven NYU patents. In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware. NYU’s complaint alleged that the AutoSetTM and AutoRampTM features of ResMed |
ResMed's (NYSE:RMD) five-year earnings growth trails the 8.2% YoY shareholder returnsWhen you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd... |
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients GloballyPublished in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low-middle income regions SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open, |
Why ResMed (RMD) is a Top Momentum Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
Resmed’s new C-suite focused on growing sleep apnea device demand: analystsAfter gaining market share during the Philips recall, Resmed can keep growing by stimulating demand through marketing initiatives and new products, William Blair analysts wrote. |